KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression

Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer. It has a poor response to conventional therapy and has an extremely poor 5-year survival rate. PDAC is driven by multiple oncogene mutations, with the highest mutation frequency being observed in KRAS. The KRAS pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zining, Zhang, Heng, Liao, Xiang, Tsai, Hsiang-i
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157181/
https://www.ncbi.nlm.nih.gov/pubmed/37152291
http://dx.doi.org/10.3389/fcell.2023.1147676

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157181/
https://www.ncbi.nlm.nih.gov/pubmed/37152291
http://dx.doi.org/10.3389/fcell.2023.1147676

Ejemplares similares